Stonepine Capital Management’s Aptevo Therapeutics APVO Stock Holding History

Stonepine Capital Management’s Portfolio APVO Stock Details APVO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q2	–	Hold	0	–	-$1.18M	–	27
2021 Q1	–	Hold	0	–	–	–	24
2020 Q4	–	Hold	0	–	–	–	20
2020 Q1	–	Sell	-1	Closed	-$2.73M	–	29
2019 Q4	$2.73M	Buy	+1	New	+$4.98M	1.91%	16
2019 Q3	–	Hold	0	–	–	–	16
2019 Q2	–	Hold	0	–	–	–	15
2019 Q1	–	Hold	0	–	–	–	16

Other funds holding APVO

TCM

Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return

RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return

KCM

Kennedy Capital Management St Louis, Missouri $5.65B AUM 61.31% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Alyeska Investment Group Chicago, Illinois $38.9B AUM 28.51% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

AFM

Anson Funds Management Dallas, Texas $1.68B AUM 373.57% 1-Year Est. Return

Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

Stonepine Capital Management's APVO Position: Q2 2021 in Review

Stonepine Capital Management held its Aptevo Therapeutics (APVO) position steady in Q2 2021 at 0 shares worth $0. The position accounts for ﹤0.01% of the portfolio, ranked #27.

Stonepine Capital Management first reported a position in APVO in Q4 2019 and has held it in 1 quarter since. The position peaked at $2.73M in Q4 2019. 1 fund tracked by Wall St. Rank holds APVO as of Q2 2021.

Stonepine Capital Management held 0 shares of Aptevo Therapeutics worth $0 as of Q2 2021.
Stonepine Capital Management left its Aptevo Therapeutics share count unchanged in Q2 2021.
Aptevo Therapeutics made up ﹤0.01% of Stonepine Capital Management's portfolio in Q2 2021, its #27 holding.
Stonepine Capital Management first reported a position in Aptevo Therapeutics in Q4 2019 and has held it in 1 quarter since.
Stonepine Capital Management's Aptevo Therapeutics position peaked at $2.73M in Q4 2019.
1 fund tracked by Wall St. Rank held Aptevo Therapeutics as of Q2 2021.

Based on Stonepine Capital Management's 13F filing for Q2 2021, filed 13 Aug 2021.